Raayu Lab Corps pilots novel computational developments to holistically improve a clinical diagnosis. Our current project focuses on a personalized, non-invasive and clinically validated diagnostic method for Alzheimer's Dementia.
A Global Problem
Alzheimer's Disease (AD), a neurodegenerative form of dementia, remains the largest public health threat to patients, families and the global economy with an estimated $1 trillion spent by 2050. However, diagnosis remains widely inaccessible due to finanical, geographical and invasive bottlenecks. While cognitive testing like the Montreal Cognitive Assesment (MoCA) and similar neuropyschological testing (MMSE) are accessible, insights are highly objective and pliable necessitating further testing. This means spending much more money, with the stress of a terminal condition looming over families, patients and their caretakers.
A Modern Solution
Raayu: Alzheimer's
Prototyping Phase
Raayu is building an XAI-powered early AD precision-diagnostic for MCI patients via. multi-modal linguistic biomarkers with neurobiological grounding. Pioneering small language models in healthcare, multi-modal deep learning architectures, and biomarker mapping for precision.
Innovation is to be validated against gold-standards, HIPAA compliant and SaMD (FDA) classified.
SLM, Multi-Modal, Brain Maps